<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Amgen Inc. | Company News & Executive Profiles - AMGN | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/amgen+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Amgen Inc.]]></description>
	<s:counts start="0" returned="10" found="1133" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Array Slips Under the Wire with $726 Million Year-End Amgen Deal]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005832/array-slips-under-the-wire-with-726-million-year-end-amgen-deal/]]></link>
		<description><![CDATA[Array BioPharma ARRY placed a risky bet at the beginning of the year, breaking biotech code and making very specific business development promises. Fortunately, it worked. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 16 Dec 2009 21:10:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+development.html"><![CDATA[Business Development]]></category>
		<category domain="http://resources.bnet.com/topic/strategic+planning.html"><![CDATA[Strategic Planning]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen, Aranesp, and anemia patients get the bad news]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/amgen-aranesp-anemia-patients-news/18588/]]></link>
		<description><![CDATA[]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 02 Nov 2009 15:13:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[trial]]></category>
		<category domain="http://resources.bnet.com/topic/cancer.html"><![CDATA[cancer]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Aranesp Suit: What Did Amgen CEO Sharer Know (and Did He Read It in His Company's PowerPoint Slides)?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005067/aranesp-suit-what-did-amgen-ceo-sharer-know-and-did-he-read-it-in-his-companys-powerpoint-slides/]]></link>
		<description><![CDATA[Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General. The suit also describes an email in which colleagues of Amgen CEO Kevin Sharer asked for information on how Amgen...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 02 Nov 2009 07:42:54 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+powerpoint.html"><![CDATA[Microsoft PowerPoint]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+excel.html"><![CDATA[Microsoft Excel]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/office+suites.html"><![CDATA[Office Suites]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Study cites concerns over Amgen drugs » Ventura County Star]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/study-cites-concerns-amgen-drugs/18402/]]></link>
		<description><![CDATA[   A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.   The study is the largest...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Sat, 31 Oct 2009 02:12:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Sued By 15 States Over Aranesp Kickbacks]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/amgen-sued-15-states-aranesp/18382/]]></link>
		<description><![CDATA[The lawsuit charges Amgen - along with a specialty group purchasing organization known as International Nephrology Network and the ASD Healthcare wholesaler - with offering kickbacks to medical providers to increase sales of its Aranesp anemia drug, Aranesp. The multi-state suit, by the way, joins a whistleblower lawsuit filed in...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 30 Oct 2009 16:04:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/anemia.html"><![CDATA[Anemia]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen's Denosumab Turned Down Again, but It May Not Be as Bad as It Seems]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004960/amgens-denosumab-turned-down-again-but-it-may-not-be-as-bad-as-it-seems/]]></link>
		<description><![CDATA[When it rains at Amgen, it pours. Days after the FDA rejected two of six approval applications for bone loss drug denosumab, it nixed the rest as well. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 22:46:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Q3: Beats Nicely, Raises Guidance]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F168140-amgen-q3-beats-nicely-raises-guidance%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Amgen AMGN reported third quarter earnings per share of $1.47, well above the Zacks Consensus Estimate of $1.26 and 21% above the year-ago earnings of $1.21. Cost cuts and a lower tax rate helped boost the top-line despite a 2% decline in total revenues, which came...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 07:23:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-355138.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions  Our first comes from the line of Geoffrey Porges &#8211; Bernstein. Geoffrey Porges &#8211; Bernstein Roger, on denosumab, treatment-induced bone loss, the FDA has asked you for PFS overall survival.  What sort of study would you do to prove that negative, and are...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 21 Oct 2009 18:30:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Amgen]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167884-earnings-preview-amgen%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Amgen AMGN is expected to report Q3 earnings Wednesday, October 21 after market open, with a conference call scheduled for 5pm ET.  Guidance Analysts are looking for EPS of $1.27 on revenue of $3.79B. The consensus range is $1.20-$1.34 for EPS, and $3.73B-$3.88B for revenue, according to First Call....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 21 Oct 2009 09:42:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Amgen Fired Manager Over Adverse Events?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/amgen-fired-manager-adverse-events/16673/]]></link>
		<description><![CDATA[Amgen fired a project manager for complaining that the pharmaceutical giant underreported "adverse events" involving "every product it markets," the man claims in a lawsuit filed in Superior Court in Ventura, Ca., Courthouse News reports. Shawn O'Brien says Amgen continues to underreport "post marketing adverse event" data to the FDA...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 20 Oct 2009 16:07:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
</channel>
</rss>
